Published in Circ Res on January 08, 2009
Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14
The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. Blood (2010) 1.35
Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol (2012) 1.06
The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Mol Immunol (2009) 0.98
Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol (2009) 0.96
Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. J Neuroinflammation (2010) 0.95
rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res (2011) 0.93
Lack of complement inhibitors in the outer intracranial artery aneurysm wall associates with complement terminal pathway activation. Am J Pathol (2010) 0.92
The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther (2011) 0.90
The protective role of CD59 and pathogenic role of complement in hepatic ischemia and reperfusion injury. Am J Pathol (2011) 0.90
Humoral innate immune response and disease. Clin Immunol (2012) 0.89
Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice. Circulation (2010) 0.88
The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2010) 0.87
NF-κB and enhancer-binding CREB protein scaffolded by CREB-binding protein (CBP)/p300 proteins regulate CD59 protein expression to protect cells from complement attack. J Biol Chem (2013) 0.86
CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. Am J Pathol (2011) 0.85
Soluble CD59 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium. PLoS One (2011) 0.83
Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev (2015) 0.82
Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes Care (2012) 0.82
Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol (2010) 0.81
Complement and HIV-I infection/HIV-associated neurocognitive disorders. J Neurovirol (2014) 0.80
The intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injury. Arterioscler Thromb Vasc Biol (2010) 0.80
Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica (Cairo) (2012) 0.80
Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression. Cardiovasc Diabetol (2016) 0.79
Complementing the inflammasome. Immunology (2016) 0.79
Mouse Cd59b but not Cd59a is upregulated to protect cells from complement attack in response to inflammatory stimulation. Genes Immun (2015) 0.76
Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice. Atherosclerosis (2014) 0.76
Identification of urinary proteins potentially associated with diabetic kidney disease. Indian J Nephrol (2016) 0.76
Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59. Immune Netw (2012) 0.75
Viral-derived complement inhibitors: current status and potential role in immunomodulation. Exp Biol Med (Maywood) (2016) 0.75
Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans. J Clin Endocrinol Metab (2014) 0.75
Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis. Comp Med (2013) 0.75
Target deletion of complement component 9 attenuates antibody-mediated hemolysis and lipopolysaccharide (LPS)-induced acute shock in mice. Sci Rep (2016) 0.75
C-reactive protein upregulates the whole blood expression of CD59 - an integrative analysis. PLoS Comput Biol (2017) 0.75
Establishment of a rat model with diet-induced coronary atherosclerosis. J Biomed Res (2016) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med (2006) 3.15
Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab (2007) 2.53
Assessment of unstable atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2007) 2.49
Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol (2002) 2.27
Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol (2005) 2.02
Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta (2003) 1.66
Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood (2001) 1.65
Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med (1994) 1.61
CD59a is the primary regulator of membrane attack complex assembly in the mouse. J Immunol (2004) 1.45
Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. J Clin Invest (2007) 1.44
Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A (2000) 1.32
Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest (1993) 1.29
Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol (1998) 1.23
Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes (2002) 1.19
Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity (2003) 1.17
Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest (1992) 1.16
Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes (2004) 1.12
Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol (2004) 1.12
C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem (2006) 1.11
Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett (2006) 1.08
Modified low density lipoproteins differentially bind and activate the C1 complex of complement. Mol Immunol (2006) 1.08
Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol (1993) 1.04
Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b. Mamm Genome (2001) 1.04
ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun (2001) 1.04
Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis (1999) 1.03
Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des (2004) 1.01
Brief report: accelerated atherosclerosis in low-density lipoprotein receptor-deficient mice lacking the membrane-bound complement regulator CD59. Arterioscler Thromb Vasc Biol (2008) 1.01
Generation and phenotyping of mCd59a and mCd59b double-knockout mice. Am J Hematol (2009) 0.98
Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin. Nat Med (2007) 0.97
Further characterization of reproductive abnormalities in mCd59b knockout mice: a potential new function of mCd59 in male reproduction. J Immunol (2005) 0.96
Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol (1996) 0.96
Retracted The mouse complement regulator CD59b is significantly expressed only in testis and plays roles in sperm acrosome activation and motility. Mol Immunol (2007) 0.95
Analysis of the promoters and 5'-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes. Genes Immun (2006) 0.91
Localization of the terminal C5b-9 complement complex in the human aortic atherosclerotic wall. Immunol Lett (1985) 0.90
IgG binding to cytoskeletal intermediate filaments activates the complement cascade. Exp Cell Res (1987) 0.88
Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol (2000) 0.88
Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis (1986) 0.86
High-level endothelial expression of human CD59 prolongs heart function in an ex vivo model of xenograft rejection. Transplantation (1998) 0.85
Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). Blood (1993) 0.82
Myocardial infarction following atherosclerosis in murine models. Curr Drug Targets (2008) 0.79
Serum C-reactive protein and complement proteins in patients with acute myocardial infarction. Immunopharmacol Immunotoxicol (2005) 0.78
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med (2009) 3.97
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature (2008) 3.93
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell (2007) 3.21
Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.01
Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol (2011) 2.83
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med (2004) 2.80
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res (2007) 2.66
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain (2008) 2.60
Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med (2007) 2.54
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48
Ultrahigh-resolution (1)H-(13)C HSQC spectra of metabolite mixtures using nonlinear sampling and forward maximum entropy reconstruction. J Am Chem Soc (2007) 2.40
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.28
Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation (2007) 2.20
Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol (2010) 2.13
Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation (2008) 2.12
Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol (2006) 2.08
Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation (2009) 2.07
Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension (2006) 2.03
Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol (2005) 2.02
Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest (2007) 2.00
Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med (2002) 1.91
Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain (2010) 1.90
Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol (2005) 1.89
Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation (2009) 1.84
Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem (2002) 1.80
Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem (2005) 1.79
IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/- mice. J Clin Invest (2011) 1.77
Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Cardiovasc Res (2012) 1.71
Influence of Helicobacter pylori infection during atherogenesis in vivo in mice. Circ Res (2002) 1.71
T-bet, a T-cell-associated transcription factor, is expressed in a subset of B-cell lymphoproliferative disorders. Am J Clin Pathol (2004) 1.70
Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res (2011) 1.69
Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population. Atherosclerosis (2011) 1.64
Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arterioscler Thromb Vasc Biol (2008) 1.64
Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis (2005) 1.59
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood (2005) 1.57
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res (2012) 1.55
T-bet, a T cell-associated transcription factor, is expressed in Hodgkin's lymphoma. Hum Pathol (2005) 1.52
Enhanced hypertension prevalence in non-Han Chinese minorities from Xinjiang Province, China. Hypertens Res (2009) 1.49
Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol (2008) 1.46
Cathepsin L activity controls adipogenesis and glucose tolerance. Nat Cell Biol (2007) 1.46
Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol (2012) 1.45
T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol (2002) 1.45
A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes. Am J Hematol (2013) 1.44
Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation (2009) 1.43
Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation (2003) 1.42
Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol (2009) 1.39
Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol (2010) 1.35
The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. Blood (2010) 1.35
Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res (2005) 1.32
Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation (2007) 1.31
Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol (2012) 1.31
The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist (2008) 1.30
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood (2005) 1.30
Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2004) 1.25
Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis (2005) 1.24
Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation (2012) 1.23
Expression of cathepsin K is regulated by shear stress in cultured endothelial cells and is increased in endothelium in human atherosclerosis. Am J Physiol Heart Circ Physiol (2006) 1.22
Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet (2001) 1.21
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol (2010) 1.20
Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc Natl Acad Sci U S A (2007) 1.20
Loss of expression of the WNT/beta-catenin-signaling pathway transcription factors lymphoid enhancer factor-1 (LEF-1) and T cell factor-1 (TCF-1) in a subset of peripheral T cell lymphomas. Am J Pathol (2003) 1.18
Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget (2012) 1.17
Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. Immunity (2003) 1.17
Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol (2011) 1.17
A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling. Circ Res (2006) 1.16
Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS One (2011) 1.15
Exercise training stimulates ischemia-induced neovascularization via phosphatidylinositol 3-kinase/Akt-dependent hypoxia-induced factor-1 alpha reactivation in mice of advanced age. Circulation (2010) 1.14
Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica (2010) 1.13
Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes (2004) 1.12
Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation (2010) 1.11
Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs. Circulation (2011) 1.11
Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev (2012) 1.11
Cathepsin K deficiency reduces elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol (2011) 1.11
Control of optical bandgap energy and optical absorption coefficient by geometric parameters in sub-10 nm silicon-nanodisc array structure. Nanotechnology (2012) 1.10
Cathepsin L activity is essential to elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol (2011) 1.09
A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J Immunol (2009) 1.09
A self-charging power unit by integration of a textile triboelectric nanogenerator and a flexible lithium-ion battery for wearable electronics. Adv Mater (2015) 1.09